Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 7/20 | 0.42 |
| ▸ | CDK19 | Q9BWU1 | 7/20 | 0.42 |
| ▸ | CCNC | P24863 | 4/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111960 | 0.93 | LMNA (0.50) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL16564794 | 0.89 | LMNA (0.49) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL23542595 | 0.83 | LMNA (0.40) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL18851640 | 0.81 | TSHR (0.56) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL519126 | 0.81 | — | — | |
| SCHEMBL15976589 | 0.81 | LMNA (0.51) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL19226488 | 0.81 | LMNA (0.51) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17886571 | 0.80 | CHRM2 (0.48) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL9963258 | 0.80 | CYP2D6 (0.48) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL30112587 | 0.80 | LMNA (0.43) | LMNACHRM2ADRA2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081310-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024006551-A2 | COVALENTLY CROSSLINKED POLYSACCHARIDES AND METHODS OF USE THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230233679-A1 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS | SIGILON THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023116527-A1 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230003706-A1 | METHODS OF EVALUATING SMALL MOLECULE-MODIFIED POLYMERS IN COMPOSITIONS | SIGILON THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2022212720-A1 | GENETICALLY MODIFIED HUMAN CELL LINES AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022170098-A2 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| WO-2010070032-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-7723341-B2 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-7723341-B2 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| EP-1874781-B1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-06-24 | — | — | EP | disclosed |
| EP-2060575-A1 | Dihydrothienopyrimidines and their use in treating inflammatory diseases | Boehringer Ingelheim International GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| WO-2006111549-A1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | DPYD, DHODH, FH | LMNA 4499/4885CHRM2 3249/4885ADRA2A 2564/4885 |
| US-20230233679-A1 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS | MYD88, CD4, CD74 | LMNA 4571/4885CHRM2 2803/4885ADRA2A 4162/4885 |
| US-20230003706-A1 | METHODS OF EVALUATING SMALL MOLECULE-MODIFIED POLYMERS IN COMPOSITIONS | FN1, MFAP1, FIBP | LMNA 158/4885CHRM2 1751/4885ADRA2A 3533/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | LMNA 95/4885CHRM2 3131/4885ADRA2A 2461/4885 |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TPMT, MALT1, IL1B | LMNA 4117/4885CHRM2 4058/4885ADRA2A 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.